KEYMAKER-U06 Substudy 06B is an open-label phase 1/2 umbrella platform trial evaluating investigational agents with or without pembrolizumab (MK-3475) and/or chemotherapy in advanced esophageal cancer. Eligible participants are adults with advanced disease previously exposed to PD-1 or PD-L1–directed therapy. The study aims to evaluate these investigational regimens in a pretreated population. The umbrella platform design allows assessment of multiple therapeutic strategies within a single protocol.
KEYMAKER-U06 Substudy 06B is a phase 1/2 open-label clinical trial. It evaluates new investigational treatments given alone or together with pembrolizumab and/or chemotherapy in advanced esophageal cancer. Adults whose cancer has previously been treated with a PD-1 or PD-L1 inhibitor can take part. The purpose of the study is to further investigate these treatment approaches. The trial uses a platform design to test different treatment strategies.
